123 related articles for article (PubMed ID: 12713607)
41. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
42. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
43. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
46. Cisplatin pharmacokinetics in children with cancer.
Peng B; English MW; Boddy AV; Price L; Wyllie R; Pearson AD; Tilby MJ; Newell DR
Eur J Cancer; 1997 Oct; 33(11):1823-8. PubMed ID: 9470840
[TBL] [Abstract][Full Text] [Related]
47. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Nakashima H; Lieberman R; Karato A; Arioka H; Ohmatsu H; Nomura N; Shiraishi J; Tamura T; Eguchi K; Shinkai T
Ther Drug Monit; 1995 Jun; 17(3):221-9. PubMed ID: 7624917
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of cisplatin and its monohydrated complex in humans.
Andersson A; Fagerberg J; Lewensohn R; Ehrsson H
J Pharm Sci; 1996 Aug; 85(8):824-7. PubMed ID: 8863271
[TBL] [Abstract][Full Text] [Related]
49. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children.
Mahmood I; Tammara V
Int J Clin Pharmacol Ther; 2004 Apr; 42(4):240-5. PubMed ID: 15124982
[TBL] [Abstract][Full Text] [Related]
50. A Bayesian approach for the estimation of pharmacokinetic parameters in children.
Mahmood I
Am J Ther; 2003; 10(2):88-92. PubMed ID: 12629586
[TBL] [Abstract][Full Text] [Related]
51. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of Bayesian estimation of pharmacokinetic parameters.
Tsuchiwata S; Mihara K; Yafune A; Ogata H
Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
[TBL] [Abstract][Full Text] [Related]
53. Constancy in integrated cisplatin plasma concentrations among pediatric patients.
Goodisman J; Souid AK
J Clin Pharmacol; 2006 Apr; 46(4):443-8. PubMed ID: 16554452
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
55. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer.
Tegeder I; Bräutigam L; Seegel M; Al-Dam A; Turowski B; Geisslinger G; Kovács AF
Clin Pharmacol Ther; 2003 May; 73(5):417-26. PubMed ID: 12732842
[TBL] [Abstract][Full Text] [Related]
57. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
de Jonge MJ; Slingerland M; Loos WJ; Wiemer EA; Burger H; Mathijssen RH; Kroep JR; den Hollander MA; van der Biessen D; Lam MH; Verweij J; Gelderblom H
Eur J Cancer; 2010 Nov; 46(16):3016-21. PubMed ID: 20801016
[TBL] [Abstract][Full Text] [Related]
58. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
60. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.
Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T
Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
